FDA DEVICE FACTS
MDx-Chex for BCN
Streck
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
MDx-Chex for BCN is intended for use as an external positive and negative assayed control to monitor the performance of the qualitative detection of Gram-negative bacteria and associated antimicrobial resistance genes, by the Diasorin LIAISON PLEX Gram-Negative Blood Culture assay on the LIAISON PLEX System. MDx-Chex for BCN Control 1 and Control 2 are composed of a buffered solution with stabilized erythrocytes and leukocytes in a matrix of blood culture media components. Control 1: Gram-negative bacteria: Acinetobacter baumannii, Haemophilus influenzae, Neisseria meningitidis, Pseudomonas aeruginosa, Stenotrophomonas maltophilia; genus: Acinetobacter spp., Pseudomonas spp.; antimicrobial resistance genes: KPC, NDM, and VIM. Control 2: Gram-negative bacteria: Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella variicola, Morganella morganii, Serratia marcescens; family/genus: Enterobacteriaceae/ Morganellaceae, Citrobacter spp., Enterobacter spp., Proteus spp., Salmonella spp.; antimicrobial resistance genes: CTX-M, IMP, MCR, OXA, and SME. This product is not intended to replace manufacturer controls provided with the device.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。